Highest-materiality recent filing
Arcadia Biosciences receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notice on Aug 4, 2026: RKDA failed minimum bid price ($1.00) for 30 consecutive business days (Jun 22–Aug 3).
CEO Thomas Schaefer received $169,000 discretionary cash bonus for 2025; no other NEOs received bonus.
Arcadia Biosciences raises $4M via private placement of pre-funded warrants and options
Sold 3.88M pre-funded warrants and Series A-1/A-2 options at $1.03 per unit, gross proceeds ~$4M.
Arcadia Q1 net loss $4.4M ($2.11/share); Zola volumes +18% YoY
Net loss attributable to common stockholders $4.385M (EPS -$2.11) vs net income $2.599M ($1.90 EPS) in Q1 2025.
Arcadia Biosciences dismisses Deloitte, hires RJI as new auditor; cites material weaknesses
Dismissed Deloitte & Touche on March 30, 2026; engaged Ramirez Jimenez International CPAs (RJI) same day.
Q4 2025 revenue $901K (-26% YoY); full-year revenue $4.86M (-4%). Net loss per share $1.71 vs $5.17 in 2024.
Arcadia Biosciences directors Bolles and Carosella resign effective Feb 4
Albert D. Bolles, Ph.D. (Compensation Committee) and Deborah Carosella (Compensation, Nominating/Governance) resigned as directors.
Arcadia Biosciences raises $2.1M via exercise of options at reduced price; issues new options
Gross proceeds of approx. $2.1M from exercise of 808,595 existing options at reduced price of $2.575/share.
Arcadia Biosciences (RKDA) merger with Roosevelt Resources terminated; no breakup fee
Received termination notice on Dec 24, 2025; Closing did not occur by Aug 15, 2025.
Arcadia Biosciences annual meeting: say-on-pay passes narrowly; directors elected with ~55% support
Approximately 51% of outstanding shares (703,677) were present at Dec 19, 2025 annual meeting.
Arcadia Q3 net income $856k vs loss $1.6M YoY; Zola YTD revenue up 26%
Q3 total revenue $1.30M, down 15% YoY; loss from operations $1.15M.
Arcadia sets 2025 annual meeting for Dec 19; proposal deadline Nov 3
Annual meeting scheduled for December 19, 2025; change of more than 30 days from 2024 meeting.
Arcadia CFO Mark Kawakami resigns; CEO Schaefer adds interim CFO role
CFO Mark Kawakami resigns effective September 12, 2025; not due to any disagreement with the Company or auditors.
Arcadia Q2 net loss $4.5M on $4.5M credit loss; Zola revenue up 24%
Total revenue $1.455M (+11% YoY); Zola coconut water sales grew 24% to $1.455M.
Arcadia Biosciences reports default on $2M note payment from Above Food Corp; buyer in receivership
Above Food Corp failed to pay $2M principal plus ~$475k interest due May 14, 2025 on note from GoodWheat sale.
Arcadia Biosciences Q1 net income $2.6M; Zola sales up 90%; Roosevelt deal amended to 90/10 split
Q1 2025 net income $2.6M ($1.90/share) vs net loss of $2.4M ($1.78 loss) in Q1 2024.
Arcadia Biosciences amends merger with Roosevelt: extends deadline, revises share formula
Termination date extended from May 15, 2025 to August 15, 2025.
Arcadia Biosciences enters agreement to receive $750,000 and transfer certain patent assets
A third party agreed to pay Arcadia $750,000 as part of the agreement.
Arcadia Biosciences Q4 revenue +56% YoY to $1.2M; net loss widens; Roosevelt deal on track
Q4 total revenues $1.216M (+56% YoY); FY2024 revenues $5.045M (+13% YoY).
Arcadia Biosciences to merge with oil and gas partnership Roosevelt Resources in all-stock deal
Signed Securities Exchange Agreement on Dec 5, 2024 for all-stock business combination with Roosevelt Resources, a Texas oil & gas partnership.
Arcadia to issue shares for all Roosevelt equity; current Arcadia shareholders will own ~10% of combined company.
Arcadia Biosciences Q3 revenue up 18% to $1.5M; net loss narrows to $1.6M
Total revenues $1.537M, +18% YoY; Zola coconut water revenue +55% YoY.
Arcadia Biosciences discloses CEO/CFO compensation: $260k/$212k salary, stock options at $2.71
CEO Thomas Schaefer base salary $260k/yr; 2024 target bonus 50% as CEO, 40% as CFO prorated.
Arcadia Q2 2024 net income $1.1M; sells wheat IP to Corteva for $4M
Q2 revenue $1.306M (flat YoY); net income $1.061M ($0.78/diluted share) vs $823K ($0.61) in Q2 2023.
Arcadia appoints CEO Thomas Schaefer to board as Class I director, filling Jacot vacancy
Thomas J. Schaefer, current president and CEO, appointed Class I director effective August 1, 2024.
Arcadia CEO Stanley Jacot resigns; CFO Schaefer promoted to CEO, Kawakami named CFO
Stanley Jacot, Jr. resigned as president, CEO, and director on July 2, 2024; cash severance $288,077 + 12-month option acceleration + COBRA through Feb 2025.
Arcadia Biosciences stockholders approve all four proposals at 2024 annual meeting
Amy Yoder elected with 160,017 votes for; Lilian Shackelford Murray with 149,613 for; 501,220 broker non-votes.
Arcadia sells GoodWheat business; receives $6M promissory note, pays $2M cash at close
Net consideration $4M: $6M promissory note (3-yr, prime rate) from Above Food; Arcadia paid $2M cash at closing.
Arcadia sells resistant starch durum wheat trait to Corteva unit for $4M cash
Sold patent and related rights for resistant starch durum wheat trait to Pioneer Hi-Bred (Corteva) for $4M cash.
Arcadia Q1 2024 revenue up 2% YoY; net loss narrows to $2.4M from $9.4M
Product revenue $1.255M (+2% YoY); fifth consecutive quarter with >30% gross margin.
Arcadia Q4 revenues up 57% to $1.2M; full-year net loss narrows to $14.0M
Q4 2023 product revenue $1.17M (+57% YoY); full-year revenue $5.33M (-28% from $7.42M due to prior-year grain sales and license revenue).
Arcadia CMO resigns effective March 1; CEO/CFO get retention bonuses of $87.5K/$65K
Laura Pitlik resigned as CMO effective March 1, 2024; receives $62,500 severance.
Arcadia Biosciences Q3 2023 revenue $1.6M, net loss $2.6M, launches GoodWheat Mac & Cheese
Revenue from continuing ops $1.597M, up 20% QoQ; net loss $2.567M ($1.89/sh) vs $2.867M ($4.67/sh) in Q3 2022.
Arcadia Q2 net income $823k on non-cash gain; revenue down 64% to $1.39M
Q2 2023 revenue $1.389M vs $3.858M in Q2 2022, down 64% due to exit of grain and body care sales.
Arcadia begins strategic review, reports $18.8M cash and Q2 revenue guidance of $1.3-1.5M
Strategic review initiated; Lake Street Capital Markets as advisor; options include sale, merger, or other transactions.
Arcadia Biosciences announces annual meeting results; all proposals approved
Directors Deborah Carosella and Gregory Waller elected with 161,465 and 166,720 votes for, respectively.
Arcadia Biosciences Q1 revenue $1.5M (down 53% YoY) but gross profit improves $922k
Total revenues $1.5M vs $3.2M; prior year included $1.8M in discontinued products.
Total revenues $9.956M, up 47% YoY; Q4 revenue $1.0M, down 54% YoY.
Arcadia Biosciences raises ~$6M in private placement at $9.00/share
Sold 666,334 shares (or pre-funded warrants) at $9.00 each, plus Series A and B investment options for up to 666,334 shares each at $9.00.
Arcadia Biosciences implements 1-for-40 reverse stock split effective March 1, 2023
Reverse stock split of common stock at 1:40 ratio, effective 12:01 a.m. ET on March 1, 2023.
Arcadia Biosciences shareholders approve reverse stock split at ratio up to 1:40
Reverse split ratio range of 1-for-10 to 1-for-40, board discretion, must occur before June 30, 2023.
Base salary $260,000 per annum; target bonus 40% of base salary as per employment letter effective Jan 3, 2023.
Declared dividend of 1/1000th share of Series A Preferred per common share; record date Dec 28, 2022, distribution Dec 29, 2022.
Arcadia Biosciences appoints Thomas Schaefer as CFO, succeeding Pamela Haley
Pamela Haley resigns as CFO effective January 3, 2023; will stay in advisory role.
Arcadia Biosciences Q3 revenue down 21% YoY to $1.9M; GoodWheat hits 1,000 stores
Q3 2022 revenue $1.9M vs $2.4M in Q3 2021, driven by lower body care/GLA, partly offset by GoodWheat pasta.
Arcadia Biosciences gets Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Arcadia on Sept 27 that common stock failed minimum $1.00 bid price for 30 consecutive days.
Arcadia Biosciences raises ~$5M via registered direct offering of common stock and warrants
Sold 4,722,506 shares at $1.05876 per share plus pre-funded warrants to an institutional investor.
Arcadia Q2 revenue surges 175% to $3.9M; net loss improves to $0.17/share
Q2 revenue $3.9M vs $1.4M a year ago, driven by Zola and GoodWheat pasta launch.
CEO Stanley E. Jacot, Jr. appointed as Class III director to fill vacancy from Matthew Plavan's Dec 2021 resignation.
Arcadia Q1 revenue $3.22M (+289% YoY), net loss $4.49M; GoodWheat launch, HB4 milestone
Q1 revenue $3.22M (+289% YoY); net loss $4.49M (vs. $2.06M income YoY on prior-year Bioceres gain)
On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.
Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.
Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.
Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.
On February 9, 2024, Laura Pitlik provided notice to Arcadia Biosciences, Inc. (“Arcadia”) of her resignation as Arcadia’s chief marketing officer, effective as of March 1, 2023 (the “Separation Date”).
On November 28, 2022, Pamela Haley provided notice to Arcadia Biosciences, Inc. (“Arcadia”) of her resignation as Arcadia’s chief financial officer, effective as of January 3, 2022.
On November 30, 2022 and effective January 3, 2022, Arcadia’s board of directors appointed Thomas J. Schaefer as Arcadia’s new chief financial officer to succeed Ms. Haley.
On June 2, 2022, Arcadia’s board of directors appointed Stanley E. Jacot, Jr., Arcadia’s current president and chief executive officer, to serve as a Class III director of the Company.
In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.
On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.
The Company has appointed Kevin Comcowich, the current chairman of the Arcadia Board of Directors, as the Company’s Interim Chief Executive Officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO.
On December 14, 2021, Matt Plavan submitted his resignation from his positions as Chief Executive Officer, President and as a member of the Board of Directors (the “Board”) of Arcadia Biosciences, Inc. (the “Company” or "Arcadia"), effective December 31, 2021 (“Separation Date”).
Max materiality 0.85 · Median 0.62 · Most common event earnings